Last Post: 01/19/2023 8:35:45 AM
Board Marks: 1
Posts Today: 0
Board Views Today: 5
BSGM BioSig Technologies Inc. (OTCQB: BSGM)
Company Website: http://biosigtech.com/
BioSig Technologies, Inc. (BSGM) is a medical device company that has developed a proprietary technology platform designed to greatly improve the rapidly growing $3 billion electrophysiology (EP) marketplace. Led by a proven management team and a veteran, independent Board of Directors, Los Angeles-based BioSig is preparing to commercialize its PURE EP™ System.
PURE EP is designed to improve outcomes of EP studies and cardiac catheter ablation, shorten procedure times and reduce recurrence rates. It is a surface electrocardiogram (ECG) and intracardiac multichannel recording and analysis system designed to assist electrophysiologists in making clinical decisions in real-time by acquiring and displaying high-fidelity cardiac signal recordings and provide guidance in identifying ablation targets – areas of tissue to destroy that otherwise create a heart rhythm disturbance (arrhythmia). BioSig believes this information is not easily obtained, if at all, from any other EP equipment in the market today.
BioSig will seek FDA 510(k) approval for its PURE EP System. The Company has achieved proof of concept validation through UCLA EP & Animal Labs ongoing from May 2013. BioSig is collaborating with several of the nation’s most prestigious cardiac arrhythmia centers to develop, refine and, ultimately, commercialize the PURE EP System, including:
Texas Cardiac Arrhythmia Institute
UCLA Cardiac Arrhythmia Center
U.H. Case Medical Center in Cleveland
William Beaumont Hospital in Michigan
Mount Sinai Medical Center in NY
Mayo Clinic in Minnesota
Company Website: http://biosigtech.com/
BioSig Technologies, Inc. (BSGM) is a medical device company that has developed a proprietary technology platform designed to greatly improve the rapidly growing $3 billion electrophysiology (EP) marketplace. Led by a proven management team and a veteran, independent Board of Directors, Los Angeles-based BioSig is preparing to commercialize its PURE EP™ System.
PURE EP is designed to improve outcomes of EP studies and cardiac catheter ablation, shorten procedure times and reduce recurrence rates. It is a surface electrocardiogram (ECG) and intracardiac multichannel recording and analysis system designed to assist electrophysiologists in making clinical decisions in real-time by acquiring and displaying high-fidelity cardiac signal recordings and provide guidance in identifying ablation targets – areas of tissue to destroy that otherwise create a heart rhythm disturbance (arrhythmia). BioSig believes this information is not easily obtained, if at all, from any other EP equipment in the market today.
BioSig will seek FDA 510(k) approval for its PURE EP System. The Company has achieved proof of concept validation through UCLA EP & Animal Labs ongoing from May 2013. BioSig is collaborating with several of the nation’s most prestigious cardiac arrhythmia centers to develop, refine and, ultimately, commercialize the PURE EP System, including:
Texas Cardiac Arrhythmia Institute
UCLA Cardiac Arrhythmia Center
U.H. Case Medical Center in Cleveland
William Beaumont Hospital in Michigan
Mount Sinai Medical Center in NY
Mayo Clinic in Minnesota
BioSig Technologies Inc. (BSGM) Research Links
BioSig Technologies Inc. (OTCMRKTS: BSGM) Stock Message Board
Post
Subject
Author
Posted On
